Intellia Therapeutics Q4 EPS $(1.46) Misses $(1.45) Estimate, Sales $(1.92M) May Not Be Comparable To $12.83M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics (NTLA) reported Q4 losses of $(1.46) per share, missing the consensus estimate of $(1.45) by 0.69%. Year-over-year, this represents a 4.29% increase in losses. Quarterly sales were $(1.92 million), significantly below the $12.83 million estimate, marking a 114.12% decrease from the previous year.
February 22, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics reported a larger than expected Q4 loss and a significant miss in sales compared to analyst estimates.
The miss in both earnings per share and sales compared to analyst estimates is likely to negatively impact investor sentiment in the short term. The significant deviation from expected financial performance, especially the sales miss by over 114%, suggests operational challenges or market conditions that could worry investors. This could lead to a decrease in stock price as the market adjusts to the new information.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100